CYCC Cyclacel Pharmaceuticals Inc

Cyclacel Pharmaceuticals Inc is a biopharmaceutical company engaged in the discovery, development and commercialization of novel, mechanism-targeted drugs to treat cancer and other serious disorders, with development operations in US and UK.

$5.78
As of 09/16/2021     IEX book   CBOE book


Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Micro cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  USA
IPO date:  03/28/2006
Outstanding shares:  9,234,110
Average volume:  134,555
Market cap:   $53,373,156
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
CUSIP:    23254L603
ISIN:        US23254L6039
Sedol:      BLR6795
Valuation   (See tab for details)
PE ratio:   0.00
PB ratio:   0.00
PS ratio:   0.00
Return on equity:   0.00%
Net income %:   0.00%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy